According to Zhitong Finance App, Yabao Pharmaceutical (600351.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 2,910 billion yuan, an increase of 7.05%; net profit attributable to shareholders of listed companies was 200 million yuan, an increase of 90.71% year on year; net profit attributable to shareholders of listed companies deducted 180 million yuan from non-recurring profit and loss, an increase of 106.11% year on year; basic earnings per share were 0.2615 yuan/share.
The company's 2023 profit distribution plan is to distribute a cash dividend of 1.5 yuan (tax included) to all shareholders for every 10 shares based on the company's total share capital on the day the equity distribution was implemented, and the remaining undistributed profits are carried over to the next year. If no shares are given, the share capital will not be transferred from the Provident Fund.